Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7-Reference-Cited by-同舟云学术

Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7

Published:2019-08-15 Issue:9 Volume:4 Page:14151-14154
ISSN:2470-1343
Container-title:ACS Omega
language:en
Short-container-title:ACS Omega

Author:

Grattan Vincent¹,Vaino Andrew R.¹,Prensky Zachary¹,Hixon Mark S.²^ORCID

Affiliation:

1. LB Pharmaceuticals Inc., 575 Madison Avenue, New York, New York 10022, United States

2. Mark S. Hixon Consulting LLC, 11273 Spitfire Road, San Diego, California 92126, United States

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.acs.org/doi/pdf/10.1021/acsomega.9b02144

Reference17 articles.

1. Enantiomeric drug development: Issues, considerations, and regulatory requirements

2. Consensus on the Use of Substituted Benzamides in Psychiatric Patients

3. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The dopamine D₂ receptors antagonist Veralipride inhibits carbonic anhydrases: solution and crystallographic insights on human isoforms;Chemistry – An Asian Journal;2024-02-26

2. Chirality of New Drug Approvals (2013–2022): Trends and Perspectives;Journal of Medicinal Chemistry;2024-02-12

3. Examination of the mechanisms underlying the discriminative stimulus properties of the atypical antipsychotic amisulpride;Behavioural Pharmacology;2023-11-16

4. A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia;Expert Review of Clinical Pharmacology;2023-10-27

5. Amisulpride as a potential disease‐modifying drug in the treatment of tauopathies;Alzheimer's & Dementia;2023-05-23